ATE428778T1 - Verfahren zum screening auf agonistische antikörper - Google Patents

Verfahren zum screening auf agonistische antikörper

Info

Publication number
ATE428778T1
ATE428778T1 AT03719213T AT03719213T ATE428778T1 AT E428778 T1 ATE428778 T1 AT E428778T1 AT 03719213 T AT03719213 T AT 03719213T AT 03719213 T AT03719213 T AT 03719213T AT E428778 T1 ATE428778 T1 AT E428778T1
Authority
AT
Austria
Prior art keywords
agonistic antibodies
screening
dependent
antibodies
effective screening
Prior art date
Application number
AT03719213T
Other languages
English (en)
Inventor
Tetsuo Kojima
Chiaki Senoo
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE428778T1 publication Critical patent/ATE428778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
AT03719213T 2002-04-26 2003-04-25 Verfahren zum screening auf agonistische antikörper ATE428778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002127260 2002-04-26
PCT/JP2003/005372 WO2003091424A1 (fr) 2002-04-26 2003-04-25 Procede de criblage d'un anticorps agoniste

Publications (1)

Publication Number Publication Date
ATE428778T1 true ATE428778T1 (de) 2009-05-15

Family

ID=29267644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719213T ATE428778T1 (de) 2002-04-26 2003-04-25 Verfahren zum screening auf agonistische antikörper

Country Status (7)

Country Link
US (1) US7732149B2 (de)
EP (1) EP1505148B1 (de)
JP (1) JP4518941B2 (de)
AT (1) ATE428778T1 (de)
AU (1) AU2003235833A1 (de)
DE (1) DE60327199D1 (de)
WO (1) WO2003091424A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874280B1 (ko) * 1999-10-20 2008-12-18 제넨테크, 인크. Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의조절
US7393532B1 (en) * 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE60233248D1 (de) * 2001-11-15 2009-09-17 Childrens Medical Center Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
AU2003235833A1 (en) 2002-04-26 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Method of screening agonistic antibody
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP3115057B1 (de) 2004-10-21 2019-09-04 ONO Pharmaceutical Co., Ltd. Verwendung eines immunsuppressiven rezeptors
KR20070095949A (ko) * 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK2824183T3 (da) * 2005-04-08 2020-09-28 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af bispecifikke antistoffer
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP3095871B1 (de) 2010-02-08 2019-04-10 Regeneron Pharmaceuticals, Inc. Maus mit gemeinen leichten ketten
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP6267689B2 (ja) 2012-05-10 2018-01-24 バイオアトラ、エルエルシー 多重特異性モノクローナル抗体
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3279216A4 (de) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptid-hetero-oligomer
EP3352760A4 (de) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3-bindende polypeptide
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
CA3035327A1 (en) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
EP3612210A4 (de) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Manipulierte antigenrezeptoren exprimierende immunzellen
EP3630156A4 (de) * 2017-05-25 2021-03-31 The Broad Institute, Inc. Lymphozyten-antigen-cd5-like (cd5l)-monomer, homodimer und interleukin 12b (p40)-heterodimer-agonisten und anwendungsverfahren dafür
MX2020002710A (es) 2017-09-29 2020-07-20 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo.
JPWO2020196926A1 (de) 2019-03-28 2020-10-01

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP3881689B2 (ja) 1992-03-11 2007-02-14 パウダージェクト ヴァクシンズ，インコーポレイテッド 免疫不全ウイルス用の遺伝子ワクチン
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
AU2333999A (en) 1998-01-23 1999-08-09 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
AU2001246934A1 (en) 2000-04-17 2001-10-30 Chugai Seiyaku Kabushiki Kaisha Agonist antibodies
AU2002210917B2 (en) 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
AU2003235833A1 (en) 2002-04-26 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Method of screening agonistic antibody

Also Published As

Publication number Publication date
WO2003091424A1 (fr) 2003-11-06
US20050164307A1 (en) 2005-07-28
DE60327199D1 (de) 2009-05-28
JP4518941B2 (ja) 2010-08-04
JPWO2003091424A1 (ja) 2005-09-02
EP1505148B1 (de) 2009-04-15
US7732149B2 (en) 2010-06-08
AU2003235833A1 (en) 2003-11-10
EP1505148A1 (de) 2005-02-09
EP1505148A4 (de) 2006-07-26

Similar Documents

Publication Publication Date Title
ATE428778T1 (de) Verfahren zum screening auf agonistische antikörper
NO20052181D0 (no) Fremgangsmate og apparat for a posisjonere et sentrum for en seismisk kilde
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
DE60308093D1 (de) Zellkultivierungsvorrichtung und diese benutzende Verfahren zur Zellsortierung
MXPA06010715A (es) Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
DE602004026435D1 (de) Verfahren und vorrichtung zum erzeugen aktualisierter software, von der ausgangs-software und den software aktualisierungskatalogen
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
DE602005007728D1 (de) Modulare Anordnung und Verfahren zum Züchten von Wassertieren
NO20053344L (no) Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
ATE404030T1 (de) Vorrichtung und verfahren zum anpasssen eines hörgeräts
DE60321356D1 (de) Verfahren zur diagnostik von eierstock endometriose
ATE544783T1 (de) Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
DE502004012314D1 (de) Verfahren zum reaktiv-färben von leder, sowie farbstoffe und deren verwendung
DE50310109D1 (de) Verfahren zum einfärben von düngemitteln
DE60215549D1 (de) Verfahren zum reinigen von kontaminiertem boden unter verwendung von mikroorganismen
DE502004007244D1 (de) Verfahren zum spezifischen schnellnachweis getr nkesch dlicher mikroorganismen
TW200641141A (en) Leather treated with fluorochemicals
ATE410056T1 (de) Vorrichtung und verfahren zum züchten von schalentieren
DE502005010139D1 (de) Verfahren zum reaktiv-färben von leder
DE60300585D1 (de) Verfahren zum Herstellen von polyolefinischer thermoplastischer Elastomerzusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties